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Major Bleeding in Patients with 
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Range on Contemporary Bleeding 
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Marco Proietti1,2, Keitaro Senoo1, Deirdre A. Lane1 & Gregory Y. H. Lip1,3
Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF). Several 
bleeding prediction scores have been described: HAS-BLED, ATRIA, HEMORR2HAGES and ORBIT. 
Of these, only HAS-BLED considers quality of anticoagulation control amongst vitamin K antagonist 
(VKA) users. We hypothesised that predictive value of bleeding risk scores other than HAS-BLED could 
be improved incorporating time in therapeutic range (TTR) in warfarin-treated patients. Of the 127 
adjudicated major bleeding events, 21.3% of events occurred in ‘low-risk’ HAS-BLED category (1.8 per 
100 patient-years), compared to higher proportions (≥50% of events; ~2.5 per 100 patient-years) in 
‘low-risk’ categories for other scores. Only the ‘low-risk’ HAS-BLED category was associated with the 
absence of investigator-defined major bleeding events (OR: 1.46;95% CI: 1.00–2.15). ‘High’ or ‘medium/
high’ risk categories for the HAS-BLED (p = 0.023) or ORBIT (p = 0.022) scores, respectively, conferred 
significant risk for adjudicated major bleeding events. On Cox regression analysis, adjudicated 
major bleeding was associated only with HAS-BLED (HR: 1.62;95% CI: 1.06–2.48) and ORBIT (HR: 
1.83;95% CI: 1.08–3.09) ‘high-risk’ categories. Adding ‘labile INR’ (TTR < 65%) to ORBIT, ATRIA and 
HEMORR2HAGES significantly improved their reclassification and discriminatory performances. In 
conclusion, HAS-BLED categorised adjudicated major bleeding events in low-risk and high-risk patients 
appropriately, whilst ORBIT and ATRIA categorised most major bleeds into their ‘low-risk’ patient 
categories. Adding TTR to ORBIT, ATRIA and HEMORR2HAGES led to improved predictive performance 
for major bleeding.
Oral anticoagulant (OAC) therapy is the cornerstone of management in patients with atrial fibrillation (AF) 
for the prevention the risk of stroke and thromboembolism1–3. Bleeding risk represents the downside of treat-
ment with anticoagulation, with a reported major bleeding incidence of 2.0 per 100 patient-years4. Therefore it 
is important to have simple and practical bleeding risk stratification tools for use in AF patients, to aid clinical 
decision-making5.
The HAS-BLED score6 is a simple, clinical risk factor based score which has been well validated in various 
cohorts7–13. Two other bleeding risk scores have been developed from large observational studies of AF pop-
ulations and subsequently validated; the ATRIA14 and the HEMORR2HAGES15 scores. The HAS-BLED score 
has been shown to be as good as–or superior to–these other (and arguably more complicated) bleeding risk 
scores11,16–18. More recently, the ORBIT bleeding score was derived from a large contemporary AF prospective 
registry19,20, with the aim to propose a simpler score to be used for the assessment of bleeding risk in AF patients, 
irrespective of the type of OAC used. The limitations of the ORBIT score have been recently discussed21.
Despite this aim, one major limitation of the ORBIT and other bleeding risk scores (apart from HAS-BLED) is 
the exclusion of labile anticoagulation control (as reflected by time in therapeutic range [TTR]) amongst vitamin 
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K antagonist (VKA, e.g. warfarin) users, despite the very strong association of poor TTR with major bleeding3,22,23. 
The VKAs are still in very widespread clinical use as OAC therapy worldwide, and clinically useful bleeding risk 
scores also need to be applicable to VKA users.
Recently we investigated the impact of TTR when added to the ORBIT and ATRIA bleeding risk scores, when 
compared to HAS-BLED, in predicting ‘clinically relevant bleeding’ in the AMADEUS Trial cohort24. Adding 
TTR to both ORBIT and ATRIA bleeding scores improved their predictive ability, although this analysis was 
hampered by a short follow-up observation, low number of adverse events and a broad definition of ‘any clinically 
relevant bleeding’ rather than focusing on major bleeding24. Thus, a separate validation study in an independent 
cohort which is adequately powered for major bleeding is needed to confirm our initial observations.
The objectives for the present analysis were as follows: (i) to perform a comprehensive comparison of the four 
AF-validated bleeding risk scores (HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES), amongst a large cohort 
of non-valvular AF patients; and (ii) to further investigate if the predictive value of bleeding risk scores other than 
HAS-BLED could be improved by incorporating TTR, if VKA was used.
Methods
We tested the HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES bleeding scores on the patients receiving war-
farin in the pooled population dataset from the Stroke Prevention using an Oral Thrombin Inhibitor in patients 
with atrial Fibrillation (SPORTIF) III and V studies25–27. The SPORTIF trials were two multicentre phase III clin-
ical trials comparing the efficacy and safety of the direct thrombin inhibitor ximelagatran, compared to warfarin, 
in predicting thromboembolic stroke in non-valvular AF patients.
De-identified datasets with patient-level information for the SPORTIF trials were obtained directly from Astra 
Zeneca, and all the analyses were performed independent of the company. All patients assigned to the warfa-
rin treatment arms and with available data for the clinical variables used to calculate the four bleeding predic-
tion scores were included in the present analysis. Detailed methods about evaluation of anticoagulation control, 
assessment of the HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES bleeding scores and study outcomes defi-
nition are reported in the web-only Supplementary Material.
We considered ‘major bleeding’ events in two distinct ways, as follows: (i) “investigator level” events (that 
included the crude number of all the major bleeding events reported by any investigator at every study site); and 
(ii) “adjudicated events” (corresponding to the final trial adjudicated major bleeding events, after the independent 
central adjudication committee evaluated all the reported events). This distinction was done in order to analyse 
the ability of bleeding scores in correctly identifying patients at low risk of bleeding, when accounting for possible 
bleeding events that could occur in “real-life” management of AF patients (ie. at the ‘prescriber’ or investigator 
level), in contrast to the strictly defined adjudicated trial protocol criteria.
Statistical Analysis. All continuous variables were tested for normality with the Shapiro-Wilk test. Variables 
with normal distribution were expressed as means and standard deviation, and tested for differences using a 
t-test. Non-parametric variables were expressed as median and interquartile range (IQR), with differences tested 
using the Mann-Whitney U test. Categorical variables, expressed as counts and percentages, were analysed by 
chi-squared test. A logistic regression analysis was performed to investigate the association between the “low risk” 
bleeding category and the clinical endpoint of “absence of major bleeding”. This analysis was performed according 
to the “investigator level” major bleeding events group.
Event-free survival analysis, assessed by an intention-to-treat approach, was performed according to bleeding 
risk categories and differences in survival distributions between subgroups were analysed using the log-rank test. 
A Cox proportional hazards analysis was used to evaluate the occurrence of major bleeding according to bleeding 
risk categories, based on “adjudicated events”.
A receiver operating characteristic (ROC) curve was compiled for all risk scores, using the major bleeding 
“adjudicated events” group, in order to evaluate the predictive ability of all models. Comparisons of ROC curves 
were performed according to De Long, De Long and Clarke-Pearson method28. Continuous net reclassification 
improvement (NRI) and integrated discriminatory improvement (IDI) were computed using the “PredictABEL” 
R package, according to methods described by Pencina et al.29.
To evaluate the impact of poor anticoagulation control amongst the bleeding scores, an additional analysis 
adding one point for TTR < 65%, was added to the ORBIT, ATRIA and HEMORR2HAGES scores to determine if 
this attributed any improvement in predictive performance for major bleeding.
Two-sided p values < 0.05 were considered statistically significant. All analyses were performed using SPSS 
v. 22.0 (IBM, NY, USA), MedCalc v. 15.6 (MedCalc Software, Belgium) and R for Mac OS X v. 3.2.1 (The R 
Foundation for Statistical Computing).
Results
In the original combined SPORTIF dataset, a total of 3,665 patients were assigned to the warfarin treatment arm; 
data to calculate the bleeding risk scores for the present analyses were available in 3,551 patients (96.9%). The 
majority of patients were male (69.5%) and the median [IQR] age was 72 [66–77] years. A total of 706 (19.9%) 
patients were treated concomitantly with aspirin, while only 20.1% of patients were VKA naïve at baseline. 
Median [IQR] CHA2DS2-VASc score was 3 [2–4], with 3,074 (86.6%) patients being categorised as ‘high risk’.
Bleeding Risk in Overall Population. Median [IQR] value in the overall study cohort for HAS-BLED 
score was 3 [2–4], while the median ORBIT, ATRIA and HEMORR2HAGES scores were 1 [0–2], 1 [1–3] and 1 
[1, 2], respectively. Distribution of patients according to the various scores on each bleeding risk schema is shown 
in Fig. 1 (Panels A–D). High bleeding risk according to HAS-BLED (score ≥ 3) was seen in 71.0% of patients; 
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whilst 7.5% of patients were at medium/high bleeding risk using the ORBIT score. The proportion of medium/
high risk patients were 2.5% for ATRIA and 41.9% for HEMORR2HAGES.
Clinical Characteristics at Baseline. Distribution of clinical characteristics according to risk catego-
ries for the various bleeding schemes are reported in eTable 1. Higher proportions of females were found in 
high or medium/high risk categories (p = 0.001 for HAS-BLED and p < 0.001 for the other scores). Coronary 
heart disease was more frequent in the high or medium/high risk categories for HAS-BLED (p < 0.001), ORBIT 
(p < 0.001) and HEMORR2HAGES (p = 0.026) but not for ATRIA (p = 0.13). No significant difference was 
found in previous stroke/transient ischemic attack between low and medium/high ATRIA categories (p = 0.065). 
Similarly, no difference in heart failure was found between the ORBIT and ATRIA score categories (p = 0.091 
and p = 0.477, respectively), or in hypertension for ORBIT score categories (p = 0.874). Thromboembolic risk 
progressively increased between risk categories for all the scores.
The proportion of patients with good anticoagulation control (TTR > 70%) progressively decreased with 
increasing risk categories for all scores, except for ATRIA (p = 0.424). The HAS-BLED low risk category had the 
highest proportion of good anticoagulation control patients (64.7% vs 38.7% in high risk category, p < 0.001).
Follow-Up Analysis. A median [IQR] follow-up of 1.6 [1.3–1.8] years yielded a total of 5,002 patient-years 
observation. A total of 162 “investigator level” major bleeding events were recorded. Of these, 127 were validated 
as “adjudicated events”, with an overall incidence of 2.5 per 100 patient-years. Event rates according to the various 
bleeding score and risk categories are shown in Table 1.
Major bleeding rates, both in the “investigator level” and “adjudicated event” groups, progressively increased as 
the bleeding risk score increased (and by bleeding risk categories) using the HAS-BLED score. Conversely, event 
rates decreased as the bleeding risk score increased and from low to medium/high bleeding risk categories, both 
for the ORBIT and ATRIA scores.
Based on the HEMORR2HAGES score, most of the events occurred in the ‘low risk’ category. Of the 127 
adjudicated major bleeding events, 21.3% of events occurred in the ‘low risk’ HAS-BLED category (1.8 per 100 
patient-years), compared to 87.4% occurring in the low risk category for ORBIT, 96.6% for ATRIA and 52.0% for 
HEMORR2HAGES (approx. 2.5 per 100 patient-years) (Table 1).
Regression and Survival Analyses. Logistic regression analysis for the absence of any ‘investigator level’ 
defined major bleeding events, found that the HAS-BLED ‘low risk’ category was associated with the absence of 
any ‘investigator level’ defined major bleeding events (low risk vs. high risk, adjusted odds ratio [OR]: 1.46, 95% 
Figure 1. Distribution of scores for the cohort utilising each bleeding risk score. 
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confidence interval [CI]: 1.00–2.13, p = 0.050). None of the other scores showed a significant association with the 
absence of any ‘investigator level’ defined major bleeding.
Analysis of bleeding scores as continuous variables, adjusted for sex and AF type, showed a significant associa-
tion with adjudicated major bleeding events for all scores (eTable 2). Survival analysis showed that patients in high 
or medium/high risk category had a higher risk for adjudicated major bleeding events for both the HAS-BLED 
(Log-Rank: 5.147, p = 0.023) and ORBIT (Log-Rank: 5.247, p = 0.022) scores. Log-rank analyses showed no sig-
nificant differences between risk categories for both ATRIA and HEMORR2HAGES scores.
After adjustment for gender and type of AF, Cox regression analyses demonstrated that a high or medium/
high risk category was significantly associated with adjudicated major bleeding for both HAS-BLED (HR: 1.62, 
95% CI: 1.06–2.48, p = 0.026) [Fig. 2, Panel A] and ORBIT (HR: 1.83, 95% CI: 1.08–3.09, p = 0.024) [Fig. 2, Panel 
B], but not for the ATRIA (HR: 1.36, 95% CI: 0.50–3.69, p = 0.544) [Fig. 2, Panel C] and HEMORR2HAGES (HR: 
1.41, 95% CI: 0.99–2.00, p = 0.057) [Fig. 2, Panel D] scores.
Performance and Reclassification Analysis. Receiver operating characteristic (ROC) curves analysis 
(eTable 3) showed that all the four scores were able to identify AF patients that reported an adjudicated major 
bleeding event. ROC curves comparison analyses showed that HEMORR2HAGES had a worse performance com-
pared both to ORBIT (z: 1.923, p = 0.054) and ATRIA (z: 2.521, p = 0.012) scores. No other statistically significant 
differences were found between the other risk scores. Based on Pencina et al.29, there was a significant negative 
reclassification with the HEMORR2HAGES score compared with ORBIT and ATRIA (NRI: − 0.2164, p = 0.016 
and NRI: − 0.3128, p < 0.001 respectively) and a loss in sensitivity in comparison with all the other bleeding 
scores based on IDI analyses (Table 2).
Impact of TTR. Modified scores, as continuous variables, were significantly associated (p < 0.001) with adju-
dicated major bleeding events (eTable 4). When considered as categorical variables, medium/high risk vs. low 
risk was also significantly associated with adjudicated events (p < 0.001 for ORBIT and ATRIA; p = 0.013 for 
HEMORR2HAGES).
Comparisons between ROC curves for the modified scores compared with their original values are summa-
rised in Table 3, and show a significant difference for the HEMORR2HAGES (p = 0.028) score with borderline 
significance for the modified ATRIA score (p = 0.052). Reclassification analysis demonstrated that by adding 
TTR < 65%, all 3 modified scores reported a significant improvement in reclassification and discrimination gain, 
with significant differences in NRI and IDI compared to their original scores that did not include TTR (Table 3). 
Major Bleeding 
Investigator Level N = 162
Major Bleeding Adjudicated 
Event N = 127
Major Bleeding 
Investigator Level N = 162
Major Bleeding Adjudicated 
Event N = 127
HAS-BLED N (%) ATRIA N (%)
 0 1 (0.6) 1 (0.8)  0 11 (6.8) 8 (6.3)
 1 7 (4.3) 3 (2.4)  1 64 (39.5) 8 (37.8)
 2 28 (17.3) 23 (18.1)  2 29 (17.9) 22 (17.3)
 3 48 (29.6) 31 (24.4)  3 54 (33.3) 45 (35.4)
 4 43 (26.5) 41 (32.3)  4 3 (1.9) 3 (2.4
 5 26 (16.0) 20 (15.7)  5 0 (0.0) 0 (0.0)
 6 9 (5.6) 8 (6.3)  6 1 (0.6) 1 (0.8)
HAS-BLED Risk N (%) ATRIA Risk N (%)
 Low 36 (22.2) 27 (21.3)  Low 158 (97.5) 123 (96.9)
 High 126 (77.8) 100 (78.7)  Medium/High 4 (2.5) 4 (3.1
HAS-BLED Risk (per 100 patient-years) ATRIA Risk (per 100 patient-years)
 Low 2.4 1.8  Low 3.3 2.5
 High 3.6 2.9  Medium/High 3.4 3.4
ORBIT N (%) HEMORR2HAGES N (%)
 0 48 (29.6) 38 (29.9)  0 9 (5.6) 6 (4.7)
 1 49 (30.2) 36 (28.3)  1 81 (50.0) 60 (47.2)
 2 47 (29.0) 37 (29.1)  2 45 (27.8) 39 (30.7)
 3 15 (9.3) 14 (11.0)  3 22 (13.6) 17 (13.4)
 4 2 (1.2) 2 (1.6)  4 4 (2.5) 4 (3.1)
 5 1 (0.6) 0 (0)  5 1 (0.6) 1 (0.8)
ORBIT Risk N (%) HEMORR2HAGES Risk N (%)
 Low 144 (88.9) 111 (87.4)  Low 90 (55.6) 66 (52.0)
 Medium/High 18 (11.1) 16 (12.6)  Medium/High 72 (44.4) 48 (48.0)
ORBIT Risk (per 100 patient-years) HEMORR2HAGES Risk (per 100 patient-years)
 Low 3.1 2.4  Low 3.0 2.2
 Medium/High 4.9 4.4  Medium/High 3.6 2.4
Table 1. Major bleeding event rates according to the bleeding risk scores.
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No significant difference was found in AUC for each of the modified scores (that included TTR), when compared 
with HAS-BLED (full data not shown).
Discussion
Our principal finding was that the different bleeding scores provided different discriminatory capacities for major 
bleeding in anticoagulated AF patients; specifically, both HAS-BLED and ORBIT categorised adjudicated major 
bleeding events in low risk and high or medium/high risk patients appropriately, but the majority of adjudi-
cated major bleeding events occurred in the ‘low risk’ ORBIT category. Second, adding a labile INR criterion 
(TTR < 65%) to ORBIT, ATRIA and HEMORR2HAGES led to improved predictive performance for major bleed-
ing compared to the original scores. Thus, both the ATRIA and ORBIT scores may perform suboptimally in iden-
tifying serious bleeding risk in a patient on warfarin, unless they are re-calibrated taking labile INRs (or TTRs) 
into consideration.
In contrast, the HAS-BLED score already considers ‘labile INR’ as one of its criteria, which is applicable 
only for a VKA user (whilst the L criterion is not applicable if a NOAC is used). The HAS-BLED score has 
been well-validated in predicting major bleeding in various clinical settings11–13,30. This score has been tested in 
untreated, aspirin, VKA11 and in non-VKA anticoagulant settings16,17,31, as well as in AF and non-AF cohorts. 
HAS-BLED is also predictive of major bleeding during bridging13 and in the setting of acute coronary syndrome 
and percutaneous coronary intervention30. Previous direct comparisons with HEMORR2HAGES15 and ATRIA14 
have showed that HAS-BLED was a good as (or even superior) in the evaluation of bleeding risk11,17,32, even in 
‘real world’ settings33 and in predicting intracranial haemorrhage (ICH)34.
The ORBIT score was derived from a large industry-sponsored observation registry that enrolled more than 
7,400 AF patients19. The authors proposed that the development of this new bleeding score would allow the eval-
uation of bleeding risk in AF patients in an easier and simplified manner compared with other scores, taking into 
consideration clinical variables easily collectible from clinical history. The score was validated in the ROCKET-AF 
trial, which was a trial of anticoagulation with rivaroxaban vs. warfarin, among high risk AF patients (only those 
with CHADS2 score ≥ 2 were included, and those with score = 2 were capped at 10%)35. Based on the published 
results the ORBIT score performed similarly in the derivation cohort and statistically better than other validated 
scores, HAS-BLED and ATRIA20. As highlighted in the accompanying Editorial21, statistical significance and clin-
ical applicability need to be balanced36. For example, a 40 year old man with prior stroke, labile INRs on warfarin 
Figure 2. Event free survival for “adjudicated event” major bleeding according to risk categories for each 
bleeding risk score. Panel (A) HAS-BLED Solid Line = High Risk; Dashed Line = Low Risk; Panel (B) ORBIT 
Solid Line = Medium/High Risk; Dashed Line = Low Risk; Panel (C) ATRIA Solid Line = Medium/High Risk; 
Dashed Line = Low Risk; Panel (D) HEMORR2HAGES Solid Line = Medium/High Risk; Dashed Line = Low 
Risk.
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(e.g. TTR 50%), concomitant use of non-steroidal anti-inflammatory drugs, abnormal liver function would have 
an ORBIT score of 0 (i.e. low risk), but would have a HAS-BLED score of 4 (high risk)21. As recommended in 
guidelines, the responsible physician would ‘flag up’ this patient with high HAS-BLED score, and in accordance 
with good clinical practice would strive to control blood pressure, optimise the TTR (or swap to a NOAC), and 
reduce concomitant drugs assumption. The ORBIT score would not ‘flag up’ such a patient (relevant to automated 
‘alert flags’ used in electronic health records) nor draw attention to the reversible bleeding risk factors.
Our study seems to confirm the illustrative case above, given that use of HAS-BLED categorised adjudicated 
major bleeding events in low risk and high risk patients appropriately, whilst the majority of major bleeding 
events occurred in patients categorised as ‘low risk’ using the ORBIT score. Also, HAS-BLED score category was 
associated with the absence of any “investigator defined” major bleeding events, whilst risk categorisation using 
the ORBIT score was not significantly associated with the absence of any investigator defined major bleeding 
events.
Consideration of poor anticoagulation control is crucial when evaluating bleeding risk. Our data clearly show 
an improved association with adjudicated major bleeding events and risk stratification for the ORBIT, ATRIA and 
HEMORR2HAGES scores when adding TTR < 65% as a measure of poor anticoagulation, with improved reclassi-
fication and discriminatory performance. Moreover, these results clearly confirm and further strengthen our pre-
vious analyses. In the AMADEUS trial cohort, adding TTR to the ORBIT and ATRIA bleeding risk score schemes 
improved their predictive abilities for clinically relevant bleeding24. Despite that, given that the AMADEUS trial 
was stopped early, and given the few major bleeding endpoints during the short follow-up period, the analysis was 
only focused on ‘any clinically relevant bleeding’.
Our study reinforces the concept that neglecting anticoagulation control, expressed by TTR, in bleeding 
assessment would led to a reduced performance of bleeding prediction scores in patients treated with VKA. 
This paper has important clinical implications as it suggests that some bleeding scores (ORBIT and ATRIA) are 
suboptimally in identifying serious bleeding risk in a patient on VKA, unless they are re-calibrated taking labile 
INRs (or TTRs) into consideration. Indeed, VKAs are still very commonly used worldwide as oral anticoagulants 
and despite the introduction of the NOACs, over-simplification of bleeding risk scores advocated to work for both 
VKAs and NOACs, but yet ignoring TTR in the VKA users, could potentially underestimate bleeding risks (and 
lead to potentially serious bleeding events). Of note, the HAS-BLED score already assigns 1 point for ‘labile INR’ 
and there was no difference in AUCs for the modified scores (adding TTR to HEMORR2HAGES, ORBIT and 
ATRIA), when compared with HAS-BLED.
Limitations. This study is mainly limited by the post-hoc, retrospective nature of our analysis and by the 
relatively short follow-up observation period, eventhough our study population was an ancillary analysis to a well 
conducted prospective randomised trial with adjudicated endpoints. Moreover, not all the factors (e.g. genetic 
factors for HEMORR2HAGES) required for scores assessment were present in our data set. In addition, we used 
only the Cockroft-Gault creatinine clearance calculation for renal function assessment, differently from the defi-
nitions used in the original score schemes. Also, study patients were carefully followed up as per the clinical trial 
protocol, risk factors would have been proactively managed, and some patients at very high bleeding risk were 
excluded due to the trial exclusion criteria. These reasons could account for the low bleeding rates seen, and the 
low event rates even amongst ‘high risk’ patients. Nonetheless, the HAS-BLED score was developed to ‘flag up’ the 
vs HAS-BLED vs ORBIT vs ATRIA
NRI p IDI p NRI p IDI p NRI p IDI p
HAS-BLED
 ORBIT − 0.0077 0.392 0 0.646
 ATRIA − 0.0883 0.323 0 0.611 0.0355 0.683 0 0.924
 HEMORR2HAGES − 0.1366 0.119 −0.0018 0.039 −0.2164 0.016 −0.0023 0.006 −0.3128 <0.001 −0.0024 0.003
Table 2.  Reclassification analysis for the various bleeding risk scores. IDI = integrated discriminatory 
improvement; NRI = net reclassification improvement.
AUC p* NRI p IDI p
vs ORBIT
ORBIT + TTR< 65%  0.609 0.106 0.2508 0.0054 0.0023 0.0092
vs ATRIA
ATRIA + TTR< 65%  0.611 0.052 0.250 0.0054 0.0020 0.0014
vs HEMORR2HAGES
HEMORR2HAGES + TTR< 65%  0.578 0.028 0.263 0.0034 0.0015 0.0016
Table 3.  Comparison of ROC curves and reclassification analysis for modified bleeding scores with 
TTR. AUC = area under the curve; IDI = integrated discriminatory improvement; NRI = net reclassification 
improvement. *z test for AUC comparison.
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patients potentially at high risk for bleeding for more careful review and follow-up so that reversible risk factors 
can be addressed (rather than let bleeding events actually occur).
Conclusion
In conclusion, the HAS-BLED score had the best predictive value in identifying those at ‘low risk’ of major 
amongst bleeding VKA-treated patients. Indeed, the majority of such bleeds occurred in patients categorised as 
‘low risk’ using the ORBIT, ATRIA and HEMORR2HAGES scores. Second, adding labile INR (i.e. TTR < 65%) 
to the ORBIT, ATRIA and HEMORR2HAGES bleeding risk scores led to their improved predictive performance 
for major bleeding.
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